Our Development Pipeline
Timber is strategically building a development pipeline in rare dermatologic diseases that have no approved treatments. Our three core development programs have all received Orphan Drug status. In addition, all of our investigational products have significant market expansion potential into major medical dermatology indications such as acne, port wine stains and tissue scarring. Clinical proof of concept has already been established in two of our mid-stage clinical development programs.
Expanded Access Statement
Timber Pharmaceutical’s current policy on expanded access is not to offer expanded access until such time that the company has thoroughly addressed the various logistical and regulatory components of such an offering. For more information, please contact email@example.com
TMB-001 (IPEG™ topical isotretinoin) is being developed for the treatment of moderate to severe subtypes of Congenital ichthyosis (CI).
TMB-002 (topical rapamycin) is being developed for the treatment of facial angiofibromas (FA) and tuberous sclerosis complex (TSC).
TMB-003 (topical sitaxentan) is under preclinical evaluation for sclerotic skin diseases.
If you are interested in any of Timber’s ongoing clinical research programs, please contact firstname.lastname@example.org.